Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 19/20 | 0.68 |
| ▸ | SLC2A3 | P11169 | 19/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | BLK | P51451 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | STK3 | Q13188 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681282 | 0.93 | SLC2A3 (0.61) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21681284 | 0.93 | SLC2A3 (0.61) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21681304 | 0.93 | SLC2A3 (0.61) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21681302 | 0.93 | SLC2A1 (0.68) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21707907 | 0.89 | SLC2A3 (0.66) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21681276 | 0.89 | SLC2A1 (0.59) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21707909 | 0.89 | SLC2A1 (0.66) | SLC2A1SLC2A3 | |
| SCHEMBL21681325 | 0.89 | SLC2A3 (0.70) | SLC2A1SLC2A3ROCK2 | |
| SCHEMBL21681296 | 0.88 | SLC2A3 (0.60) | SLC2A1SLC2A3ROCK2CLK2BLK | |
| SCHEMBL21681294 | 0.88 | SLC2A3 (0.60) | SLC2A1SLC2A3ROCK2CLK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | claimed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | claimed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | SLC2A3, SLC2A4, SLC2A1 | SLC2A1 3/4885SLC2A3 1/4885ROCK2 4166/4885 |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | SLC2A3, SLC2A4, SLC2A1 | SLC2A1 3/4885SLC2A3 1/4885ROCK2 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.